APRESAZIDE Drug Patent Profile
✉ Email this page to a colleague
When do Apresazide patents expire, and when can generic versions of Apresazide launch?
Apresazide is a drug marketed by Novartis and is included in three NDAs.
The generic ingredient in APRESAZIDE is hydralazine hydrochloride; hydrochlorothiazide. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for APRESAZIDE?
- What are the global sales for APRESAZIDE?
- What is Average Wholesale Price for APRESAZIDE?
Summary for APRESAZIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 134 |
| Patent Applications: | 3,756 |
| DailyMed Link: | APRESAZIDE at DailyMed |
US Patents and Regulatory Information for APRESAZIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | APRESAZIDE | hydralazine hydrochloride; hydrochlorothiazide | CAPSULE;ORAL | 084735-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | APRESAZIDE | hydralazine hydrochloride; hydrochlorothiazide | CAPSULE;ORAL | 084810-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | APRESAZIDE | hydralazine hydrochloride; hydrochlorothiazide | CAPSULE;ORAL | 084811-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
